Assessment of the efficacy and safety profile of correcting metabolic disorders and intestinal dysbiosis using “Bactizym Enzymbiotic” in patients with metabolic syndrome
The prevalence of obesity and associated metabolic syndrome has reached global epidemic proportions. The intestinal microbiota is a key modulator of not only nutritional status but also systemic inflammation, lipid, and carbohydrate metabolism. Enzymbiotics, which combine enzymes, prebiotics, and metabiotics, represent a promising approach for the correction of metabolic syndrome. Objective: To evaluate the efficacy and safety of Bactizym Enzymbiotic in the correction of metabolic disorders and the intestinal microbiome in patients with metabolic syndrome. Materials and Methods: A total of 138 patients with metabolic syndrome were examined (study group: n=92, treated with Bactizym Enzymbiotic for 1 month; comparison group: n=46, no treatment). The dynamics of body mass index, bioimpedance analysis (visceral fat), lipidograms, carbohydrate and hormonal profiles, Colonoflor 16 intestinal microbiota PCR, metabolomics parameters, anxiety, and appetite were studied. Results. Compared to the control group, 65% of patients in the study group reported an improvement in well-being, while 16% experienced a decrease in appetite. A decrease in waist circumference (Δ -3.8 cm, p < 0.05) and visceral fat (Δ -27.4%, p < 0.01) was noted, as were improved sleep quality and decreased anxiety (Δ -33,3%, p<0.01), as well as a decrease in triglyceride levels (Δ -29.5%, p < 0.05), and an increase in Bacteroides spp. and Akkermansia muciniphila (p=0.02 and p=0.05), a significant decrease in HOMA-IR (Δ -36.4%, p<0.01), LPS endotoxemia (Δ -54.9%, p<0.001), an increase in GLP-1 (Δ +61.9%, p<0.001) and adiponectin (Δ +57.4%, p<0.001). Conclusion. The use of Bactizym Enzymbiotic is associated with a multisystemic positive effect: correction of dysbiosis, reduction of metabolic endotoxemia, improvement of insulin resistance and atherogenic profile, modulation of the gut-brain axis. The drug can be considered an effective and safe component of MS therapy.
Authors
- Elena Vladimirovna Khazova (ORCID: https://orcid.org/0000-0001-8050-2892)
- A. A. Sinitsa
- G. I. Esipovich (ORCID: https://orcid.org/0009-0007-4990-7390)
- S. A. Pegova (ORCID: https://orcid.org/0009-0004-1285-7623)
- I. A. Fakhrutdinov (ORCID: https://orcid.org/0000-0002-3025-7574)
- L. I. Alikhanova (ORCID: https://orcid.org/0009-0005-3671-857X)
Institutions
- Kazan State Medical University (RU)
Publication Details
- Journal
- Экспериментальная и клиническая гастроэнтерология
- Published
- 2026-11-18
- DOI
- https://doi.org/10.31146/1682-8658-ecg-248-4-42-49
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00